ImmunoPrecise Antibodies (IPA) Competitors $0.42 -0.06 (-12.57%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends IPA vs. TARA, OCX, AADI, AFMD, UNCY, ANEB, ATRA, SRZN, CLNN, and RLYBShould you be buying ImmunoPrecise Antibodies stock or one of its competitors? The main competitors of ImmunoPrecise Antibodies include Protara Therapeutics (TARA), OncoCyte (OCX), Aadi Bioscience (AADI), Affimed (AFMD), Unicycive Therapeutics (UNCY), Anebulo Pharmaceuticals (ANEB), Atara Biotherapeutics (ATRA), Surrozen (SRZN), Clene (CLNN), and Rallybio (RLYB). These companies are all part of the "pharmaceutical products" industry. ImmunoPrecise Antibodies vs. Protara Therapeutics OncoCyte Aadi Bioscience Affimed Unicycive Therapeutics Anebulo Pharmaceuticals Atara Biotherapeutics Surrozen Clene Rallybio ImmunoPrecise Antibodies (NASDAQ:IPA) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment, community ranking and analyst recommendations. Does the media favor IPA or TARA? In the previous week, ImmunoPrecise Antibodies had 1 more articles in the media than Protara Therapeutics. MarketBeat recorded 1 mentions for ImmunoPrecise Antibodies and 0 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 0.80 beat ImmunoPrecise Antibodies' score of 0.00 indicating that Protara Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment ImmunoPrecise Antibodies Neutral Protara Therapeutics Positive Which has preferable valuation and earnings, IPA or TARA? ImmunoPrecise Antibodies has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than ImmunoPrecise Antibodies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunoPrecise Antibodies$18.16M0.66-$20.13M-$0.78-0.54Protara TherapeuticsN/AN/A-$40.42M-$3.19-0.77 Do institutionals & insiders have more ownership in IPA or TARA? 6.7% of ImmunoPrecise Antibodies shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 6.8% of ImmunoPrecise Antibodies shares are held by insiders. Comparatively, 12.5% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor IPA or TARA? Protara Therapeutics received 23 more outperform votes than ImmunoPrecise Antibodies when rated by MarketBeat users. However, 90.91% of users gave ImmunoPrecise Antibodies an outperform vote while only 64.71% of users gave Protara Therapeutics an outperform vote. CompanyUnderperformOutperformImmunoPrecise AntibodiesOutperform Votes1090.91% Underperform Votes19.09%Protara TherapeuticsOutperform Votes3364.71% Underperform Votes1835.29% Do analysts rate IPA or TARA? ImmunoPrecise Antibodies currently has a consensus target price of $6.00, indicating a potential upside of 1,337.13%. Protara Therapeutics has a consensus target price of $24.00, indicating a potential upside of 871.66%. Given ImmunoPrecise Antibodies' higher probable upside, analysts plainly believe ImmunoPrecise Antibodies is more favorable than Protara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmunoPrecise Antibodies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Protara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, IPA or TARA? ImmunoPrecise Antibodies has a beta of 0.09, indicating that its share price is 91% less volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500. Is IPA or TARA more profitable? Protara Therapeutics has a net margin of 0.00% compared to ImmunoPrecise Antibodies' net margin of -114.67%. Protara Therapeutics' return on equity of -55.03% beat ImmunoPrecise Antibodies' return on equity.Company Net Margins Return on Equity Return on Assets ImmunoPrecise Antibodies-114.67% -65.37% -40.29% Protara Therapeutics N/A -55.03%-48.27% SummaryImmunoPrecise Antibodies beats Protara Therapeutics on 8 of the 15 factors compared between the two stocks. Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Get ImmunoPrecise Antibodies News Delivered to You Automatically Sign up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPA vs. The Competition Export to ExcelMetricImmunoPrecise AntibodiesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.04M$7.42B$5.50B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-0.5410.05116.1015.23Price / Sales0.66400.761,496.2597.74Price / CashN/A47.3939.7434.10Price / Book0.455.594.775.07Net Income-$20.13M$153.56M$119.06M$225.46M7 Day Performance-38.43%0.13%0.80%0.37%1 Month Performance-28.63%15.23%5.65%3.57%1 Year Performance-78.14%41.14%36.75%29.43% ImmunoPrecise Antibodies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPAImmunoPrecise Antibodies3.2946 of 5 stars$0.42-12.6%$6.00+1,337.1%-80.3%$12.04M$18.16M-0.5480Gap DownTARAProtara Therapeutics2.1907 of 5 stars$2.51flat$24.00+856.2%+105.8%$51.78MN/A-0.7930Positive NewsOCXOncoCyte2.1855 of 5 stars$3.03+0.3%$4.06+34.1%+29.3%$51.00M$1.50M0.00120Analyst ForecastAADIAadi Bioscience4.2122 of 5 stars$2.01+1.0%$10.25+410.0%-53.9%$49.47M$24.35M-0.8340Upcoming EarningsAFMDAffimed3.7573 of 5 stars$3.23flat$20.00+519.2%-8.3%$49.19M$8.95M0.0076News CoverageUNCYUnicycive Therapeutics3.0099 of 5 stars$0.52-2.8%$5.13+885.8%-10.7%$49.06M$680,000.00-0.509Gap UpANEBAnebulo Pharmaceuticals3.2578 of 5 stars$1.88+1.6%$8.00+325.5%-16.3%$48.75MN/A-5.884Gap DownHigh Trading VolumeATRAAtara Biotherapeutics3.5805 of 5 stars$9.18+3.0%$14.00+52.5%-69.2%$45.07M$8.57M-0.23165Upcoming EarningsGap UpSRZNSurrozen2.0611 of 5 stars$13.97+3.9%N/A+113.9%$44.84M$12.50M0.0042CLNNClene3.6525 of 5 stars$6.50+2.4%$72.33+1,012.8%-19.1%$44.59M$650,000.00-1.46100Upcoming EarningsRLYBRallybio3.1454 of 5 stars$1.07+3.9%$10.00+834.6%-76.1%$44.39MN/A-0.6040Analyst Forecast Related Companies and Tools Related Companies Protara Therapeutics Alternatives OncoCyte Alternatives Aadi Bioscience Alternatives Affimed Alternatives Unicycive Therapeutics Alternatives Anebulo Pharmaceuticals Alternatives Atara Biotherapeutics Alternatives Surrozen Alternatives Clene Alternatives Rallybio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IPA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoPrecise Antibodies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoPrecise Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
